A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Pertuzumab/trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab; Trastuzumab
- Indications Early breast cancer; Male breast cancer
- Focus Pharmacokinetics; Registrational
- Sponsors Roche
- 26 Jul 2018 According to a Halozyme Therapeutics media release, the first patient has been dosed in the trial.
- 01 Jun 2018 Status changed from not yet recruiting to recruiting.
- 16 Apr 2018 New trial record